Home / Executive Moves / CIBER Appoints Ex-IBM Exec Rick Genovese as EVP of North American Operations

CIBER Appoints Ex-IBM Exec Rick Genovese as EVP of North American Operations

CIBER, Inc. (NYSE: CBR) has appointed Rick Genovese as executive vice president of its north american operations, effective Sept. 6, 2011.

Genovese will be responsible for strategy, delivery and full profit and loss performance of the operating segment, which accounted for 45 percent of CIBER’s revenue in 2010.

Genovese has more than 30 years of business development and senior operating leadership experience, most recently at IBM (NYSE: IBM) where he served as general manager of application services for the Americas.

He previously was managing partner of IBM’s global business services communications sector.

Prior to that, Genovese was managing partner for the global energy consulting practice at Price Waterhouse C0oper, where he was admitted as a partner in 1990.

Genovese began his career as a principal at Electronic Data Systems.

“Rick has proven his mettle in professional business and IT services, serving in operational leadership roles at two of the powerhouse brands in the industry, ” said CIBER CEO Dave Peterschmidt. “He has the business discipline, sales and delivery expertise, unwavering client focus and multifunctional business experience in both growth and turn-around situations to drive CIBER’s North American operations to a whole new level of performance and profitability.”

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.